Skip to main content
Beijing Biostar Pharmaceuticals Co., Ltd. logo

Beijing Biostar Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 2563 ISIN · CNE100006NB3 HKEX Manufacturing
Open in API
Filings indexed 101 across all filing types
Latest filing 2026-05-21 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2563

About Beijing Biostar Pharmaceuticals Co., Ltd.

http://www.biostar-pharm.com

Beijing Biostar Pharmaceuticals Co., Ltd. is a high-tech biopharmaceutical company specializing in the research, development, production, and commercialization of innovative oncology drugs. The company leverages synthetic biology technology, utilizing proprietary platforms such as combinatorial biosynthesis and microbial fermentation production to develop novel anti-cancer treatments. Its core product, Utidelone, is the subject of global clinical trials targeting various solid tumors, including advanced gastric cancer, advanced ovarian cancer, and breast cancer (including triple-negative breast cancer and brain metastasis). Utidelone has also received FDA Orphan Drug Designation for pancreatic cancer, reflecting the company's focus on addressing cancers with high unmet medical needs.

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 87% confidence The document is a Hong Kong Stock Exchange announcement providing detailed disclosure and clarifications on the subscription of new shares under the company’s general mandate. It focuses on the issuance of equity, subscription price, terms of the subscription agreement, use of proceeds, and related share capital changes. This fits squarely within the “Share Issue/Capital Change” category.
2026-05-21 English
PROPOSED ADOPTION OF SHARE OPTION SCHEME AND PROPOSED MANDATE TO THE BOARD AND/OR AUTHORISED PERSON TO HANDLE MATTERS PERTAINING TO THE SHARE OPTION SCHEME
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the proposed adoption of a Share Option Scheme by the Board of Beijing Biostar Pharmaceuticals Co., Ltd. It details the purpose, conditions, duration, administration, participants, restrictions, lapse conditions, clawback mechanism, subscription price, limits, performance targets, exercise timing, vesting period, and rights attached to the options. This is a corporate announcement about a share-based incentive plan, which relates to capital structure and equity incentives. It is not a financial report, earnings release, or regulatory filing about financial results or governance changes. It is also not a proxy solicitation or voting results announcement. The document is a detailed announcement about a capital-related scheme, specifically a share option scheme, which fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed terms, not just a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2026-05-07 English
SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the subscription of new shares under a general mandate by Beijing Biostar Pharmaceuticals Co., Ltd. It details the subscription agreement, parties involved, subscription price, conditions precedent, closing, ranking of shares, general mandate, application for listing, CSRC filings, reasons and benefits of the subscription, use of proceeds, and effects on shareholding structure. The content focuses on a capital raising event through issuance of new shares and related financing details. There is no financial statement or comprehensive financial report included, nor is it a regulatory certification or voting result announcement. The document is a detailed update on a financing activity involving new share issuance under a general mandate. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-05-07 English
VOLUNTARY ANNOUNCEMENT - INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE
Transaction in Own Shares Classification · 100% confidence The document is a voluntary announcement by Beijing Biostar Pharmaceuticals Co., Ltd. regarding the Board's resolution to repurchase the company's H shares on the open market. It references the 2025 AGM where a repurchase mandate was granted, and discusses the intention and conditions for the share repurchase. The document does not contain financial statements or detailed financial data but is an announcement of a planned capital action (share repurchase). The document length is 3439 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of a Transaction in Own Shares (POS) filing, which covers company announcements about share buybacks or repurchases.
2026-05-07 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing for an equity issuer listed on the Hong Kong Stock Exchange, detailing movements in share capital, issued shares, treasury shares, and public float sufficiency confirmation. It includes specific data on share capital balances, confirmations of compliance with public float requirements, and notes on share repurchases and cancellations. The document is a regulatory submission related to share capital and shareholding movements, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication but a regulatory filing required by the exchange. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-05-06 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Beijing Biostar Pharmaceuticals Co., Ltd. It details changes in authorised/registered share capital, issued shares, treasury shares, and public float sufficiency confirmation for the month ended 31 March 2026. The document is a regulatory compliance report related to share capital and shareholding movements, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication but a substantive regulatory filing required by the exchange rules. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-05-06 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.